ImmunityBio, Inc. Common Stock

IBRXNASDAQ • USD
6.02 USD
↘ 0.05 (0.82%)AT CLOSE (03:59 PM EST)
6.04
↗ 0.02 (0.35%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
6.04
↗ 0.02 (0.35%)
🔴Market: CLOSED

IBRX is currently priced at $6.02. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, exceptional Return on Equity (96.8%) and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Nov 13, 2026.

Open?$6.11
High?$6.17
Low?$5.83
Prev. Close?$6.07
Volume?13.3M
Avg. Volume?14.5M
VWAP?$6.01
Rel. Volume?0.92x
Bid / Ask
Bid?$6.03 × 600
Ask?$6.07 × 100
Spread?$0.04
Midpoint?$6.05
Valuation & Ratios
Market Cap?6.4B
Shares Out?1.1B
Float?394.2M
Float %?37.2%
P/E Ratio?N/A
P/B Ratio?-5.59
EPS?-$1.04
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Employees
691
Market Cap
6.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-03-10
Address
3530 JOHN HOPKINS COURT
SAN DIEGO, CA 92121
Phone: (844) 696-5235
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
87
Short Sent.?
10
Piotroski F-Score?1/9Weak
Altman Z-Score?-9.33Distress
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?31.99%Squeeze Risk
Short Interest?126.1M
Days to Cover?10.8
Free Float394.2M
Avg Daily Volume11.7M
Settlement Date2026-10-30
Financial Health
Current Ratio?4.27Strong
Quick Ratio?4.27Strong
Cash Ratio?0.46Low
Debt/Equity?-0.37Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-5.59CHEAP▾
P/S?
Peers
100
S&P
3
35.08HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-26.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
37.17HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
96.8%STRONG▾
ROA?
S&P
3
-182.1%WEAK▾
Cash Flow & Enterprise
FCF?$-296686000
Enterprise Value?$6.8B
Fundamentals ratios updated end of day